You just read:

OncoGenex Announces Completion of a Special Protocol Assessment (SPA) Amendment with the FDA Increasing Patient Eligibility for the Custirsen Phase III Prostate Cancer SATURN Clinical Trial

News provided by

OncoGenex Pharmaceuticals

Sep 19, 2011, 08:28 ET